InflaRx's peer-reviewed paper confirms earlier positive Phase 1 findings for izicopan, supporting its development. The 86 participants were healthy, so the study does not show whether the drug helps patients.
Peer review adds support for izicopan's early safety and drug-level findings. The study involved healthy people, so it does not show whether the drug treats ANCA-associated vasculitis or other kidney diseases.
Follow InflaRx N.V. (IFRX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IFRX